OKL-1111 is under clinical development by Alveron Pharma and currently in Phase I for Brain Hemorrhage. According to GlobalData, Phase I drugs for Brain Hemorrhage does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OKL-1111 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OKL-1111 overview

OKL-1111 is under development for the treatment of intracranial haemorrhage (ICH). It is administered through parenteral route as a solution. The drug candidate is a procoagulant cyclodextrin derivative.

Alveron Pharma overview

Alveron Pharma (Alveron) is a producer of drugs. The company’s offerings include cyclodextrins (CDs) and procoagulant cyclodextrins and it treats various types of thromboembolic disorders. Its technology manufactures cyclodextrins and procoagulant cyclodextrins to treat excessive bleeding, hemophilia, trauma, surgery, and anti-coagulants-usage bleeding, enabling medical practitioners to provide therapy for the acute and long-term prevention and treatment of numerous types of thromboembolic disorders. Alveron drug OKL-111 is positioned as a rapid first line therapy and is being developed as a ready to use solution for injection. The company operates in netherlands. Alveron is headquartered in Nijmegen, Gelderland,The Netherlands.

For a complete picture of OKL-1111’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.